Abstract
1. Eight healthy volunteers and eight patients suffering from chronic obstructive pulmonary disease (COPD) received 30 mg prednisolone as plain (P) and enteric-coated tablets (EP) in a randomised, cross-over manner. Plasma prednisolone and cortisol and blood glucose were measured over 24 h. 2. Although absorption of prednisolone was considerably slower when administered as the enteric-coated form, peak plasma drug concentrations and total AUC (0,24 h) were equivalent for the two formulations. Malabsorption of prednisolone was not observed. 3. The administration of EP was associated with significantly less adrenal suppression in volunteers than P as judged by measurement of AUC (0,24 h) values for endogenous cortisol. However, this difference did not reach statistical significance in the patient group. 4. Plasma cortisol concentrations declined more slowly following administration of the enteric-coated form to both groups. The difference in time taken (median and range) to maximum suppression of cortisol was statistically significant (P less than 0.05) between P (2.5 h; 2-4 h) and EP (4 h; 3-12 h) preparations administered to volunteers. There was a similar significant difference (P less than 0.05) between P (2.5 h; 1-4 h) and EP (7 h; 2-12 h) in the patients. 5. Plasma cortisol concentrations were significantly lower at 24 h in patients receiving the enteric-coated product in association with higher terminal prednisolone concentrations. 6. Blood glucose concentrations increased over an 8 h period in both groups.(ABSTRACT TRUNCATED AT 250 WORDS)
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Hayes M., Alam A. F., Bruckner F. E., Doherty S. M., Myles A., English J., Marks V., Chakraborty J. Plasma prednisolone studies in rheumatic patients. Ann Rheum Dis. 1983 Apr;42(2):151–154. doi: 10.1136/ard.42.2.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hulme B., James V. H., Rault R. Absorption of enteric and non-enteric coated prednisolone tablets. Br J Clin Pharmacol. 1975 Aug;2(4):317–320. doi: 10.1111/j.1365-2125.1975.tb02777.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- KAMMERER W. H., FREIBERGER R. H., RIVELIS A. L. Peptic ulcer in rheumatoid patients on corticosteroid therapy; a clinical, experimental and radiologic study. Arthritis Rheum. 1958 Apr;1(2):122–141. doi: 10.1002/art.1780010205. [DOI] [PubMed] [Google Scholar]
- Kong A. N., Ludwig E. A., Slaughter R. L., DiStefano P. M., DeMasi J., Middleton E., Jr, Jusko W. J. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin Pharmacol Ther. 1989 Dec;46(6):616–628. doi: 10.1038/clpt.1989.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mant T. G. Investigation of a case of prednisolone malabsorption. Postgrad Med J. 1979 Jun;55(644):421–422. doi: 10.1136/pgmj.55.644.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
- May C. S., Caffin J. A., Halliday J. W., Bochner F. Prednisolone pharmacokinetics in asthmatic patients. Br J Dis Chest. 1980 Jan;74(1):91–92. [PubMed] [Google Scholar]
- Olivesi A. Non-absorption of enteric-coated prednisolone. Normal absorption of non-enteric-coated prednisolone in a patient with Crohn's disease and massive intestinal resection. Therapie. 1985 Jan-Feb;40(1):5–7. [PubMed] [Google Scholar]
- WEST H. F. Prevention of peptic ulceration during corticosteroid therapy. Br Med J. 1959 Oct 10;2(5153):680–680. doi: 10.1136/bmj.2.5153.680. [DOI] [PMC free article] [PubMed] [Google Scholar]